All News

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of LUNGevity about the chemotherapy shortage and its impact on patients with lung cancer.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of Lungevity about advancements in treatments for small cell lung cancer.

As part of its Speaking Out video series, CURE® spoke with Brandon Leonard of the LUNGevity Foundation about the role legislation can play in a patient’s cancer journey.

My faith has helped guide me through chronic small lymphocytic lymphoma.

While CDK4/6 inhibitors are “liberating” for this breast cancer subset, questions remain about what to do in later lines of therapy, according to a presentation at the CURE® Educated Patient Breast Cancer Summit.

I recently heard a story about a patient's personality change because of cancer, and it reminded me of the hyperactive delirium I experienced.

Eating a plant-based diet has been associated with sustained MRD negativity for patients with multiple myeloma.

With cyberattacks on medical institutions on the rise, CURE® spoke with an online security expert about steps patients should take if they believe their data has been exposed.

An expert explained that patients with breast cancer who undergo genetic testing may help their family members, regardless of whether patients have children.

Some patients are forced to deal with “infuriating” attempts at exploitation while navigating their disease.

When innovation meets creativity, you never know what might happen, notably as a breast cancer survivor!

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

My prostate cancer has come back and stronger, but so have I.

Certain patients with lung cancer who have EGFR exon 20 insertion mutations may have a new treatment option, which welcomes a new “milestone.”

An expert spoke with CURE® about the next steps for patients recently diagnosed with prostate cancer and the types of treatments they may receive.

Although many hate drinking the prep for colonoscopies, I view it as a privilege.

The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

A patient received a dose of the novel menin inhibitor, ziftomenib, plus Xospata in a phase 1 trial for patients with AML.

This poem was written in hope that those experiencing multiple myeloma, or other cancers, will find solace in knowing that advancements in treatments are being made every day, and a positive attitude with caregiver acceptance and support will prolong one’s days for a productive life.

As a three-time cancer survivor, I wonder: are my roots damaged or resting to find their way?

Genetic mutations that initially were classified as having undetermined significance may now point toward an increased risk of cancer, highlighting the importance of multigene testing after a diagnosis.

An expert gives an overview of common endocrine-related side effects that premenopausal women with breast cancer may experience — and what can be done to address them.

Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.

Even though multiple myeloma had devastating effects on my collapsed lungs, singing has helped regain my sense of strength and resilience.

From Jason Kelce honoring the team trainer who has been diagnosed with cancer to deaths in the sports reporting and music world, here’s what’s happening in the oncology space this week.

When I had cancer for the third time, I spent afternoons resting in my room, watching and listening to the sounds of nature.

The Food and Drug Administration approved Brukinsa plus Gazyva for patients with relapsed or refractory follicular lymphoma who have undergone two or more prior lines of therapy.